Peter A. Friedli
Founder at NEW VENTURETEC AG
Profile
Peter A.
Friedli is the founder of Osiris Therapeutics, Inc. (founded in 1992) where he served as Chairman from 1992 to 2019.
He is also the founder of Invenda Corp.
(founded in 1996) where he currently holds the position of Director.
Additionally, he is the founder of New Venturetec AG (founded in 1997) where he currently holds the position of Chairman and Chairman of the Board of Directors.
Mr. Friedli's current job(s) include being a Director at Vertical Circuits, Inc. and a Director at Prolexys Pharmaceuticals, Inc.Mr. Friedli's former job(s) include being the Chief Executive Officer at Pine Investments AG (from 1986 to 2012), Chairman at Inflabloc Pharmaceuticals, Inc., Chairman at ReVerb Networks, Inc., Director at mPortal, Inc., and President at Venturetec, Inc.
Peter A. Friedli active positions
Companies | Position | Start |
---|---|---|
NEW VENTURETEC AG | Founder | 1997-07-15 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | Founder | 1995-12-31 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Director/Board Member | - |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | Director/Board Member | - |
New Venturetec AG /Venture Capital/
New Venturetec AG /Venture Capital/ Investment ManagersFinance New Venturetec AG is a venture capital firm was founded by Peter A. Friedli on August 11, 1997 and is headquartered in Zug, Switzerland. | Founder | 1997-08-07 |
Former positions of Peter A. Friedli
Companies | Position | End |
---|---|---|
OSIRIS THERAPEUTICS, INC. | Founder | 2019-04-16 |
Pine Investments AG
Pine Investments AG Investment ManagersFinance Friedli Corporate Finance AG (Friedli CF) is a venture capital holding and management firm established in 1986 and based in Zurich. The firm manages the Venturetec funds as well as a portfolio of private equity participations, through Madison Partners SA which is their New York-based subsidiary. Madison Partners is controlled by Peter Friedli and the minority shareholder is Kevin Kimberlin, the chairman of the venture capital firm Spencer Trask & Co. Friedli CF's investors include banks, pension funds and corporations, primarily based in Switzerland. | President | 2012-08-12 |
ReVerb Networks, Inc.
ReVerb Networks, Inc. BroadcastingConsumer Services ReVerb Networks, Inc. develops and designs an integrated radio and antenna systems. The company was founded in 2007 and is headquartered in Sterling, VA. | Chairman | - |
mPortal, Inc.
mPortal, Inc. Packaged SoftwareTechnology Services mPortal, Inc. designs and develops mobile content and applications. Its mobile network operators, moble virtual network operators, cable operators, content providers, and business enterprises. The company was founded in 2000 and is headquartered in McLean, VA. | Director/Board Member | - |
░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 11 |
---|---|
Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | Commercial Services |
Venturetec, Inc. | |
New Venturetec AG
New Venturetec AG Investment ManagersFinance New Venturetec AG is an investment and holding company, which engages in holding a direct and indirect investments in the biotechnology companies. It also obtains capital appreciation from well-selected companies that are at the forefront of the technology and products. The company was founded by Peter A. Friedli on July 16, 1997 and is headquartered in Zug, Switzerland. | Finance |
Inflabloc Pharmaceuticals, Inc.
Inflabloc Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Inflabloc Pharmaceuticals, Inc. engages in the research and development of pharmaceutical treatments. It develops products for the treatment of gastrointestinal disorders and inflammatory diseases. The company was founded in 1991 and is headquartered in Salt Lake City, UT. | Commercial Services |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | Electronic Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
mPortal, Inc.
mPortal, Inc. Packaged SoftwareTechnology Services mPortal, Inc. designs and develops mobile content and applications. Its mobile network operators, moble virtual network operators, cable operators, content providers, and business enterprises. The company was founded in 2000 and is headquartered in McLean, VA. | Technology Services |
Pine Investments AG
Pine Investments AG Investment ManagersFinance Friedli Corporate Finance AG (Friedli CF) is a venture capital holding and management firm established in 1986 and based in Zurich. The firm manages the Venturetec funds as well as a portfolio of private equity participations, through Madison Partners SA which is their New York-based subsidiary. Madison Partners is controlled by Peter Friedli and the minority shareholder is Kevin Kimberlin, the chairman of the venture capital firm Spencer Trask & Co. Friedli CF's investors include banks, pension funds and corporations, primarily based in Switzerland. | Finance |
ReVerb Networks, Inc.
ReVerb Networks, Inc. BroadcastingConsumer Services ReVerb Networks, Inc. develops and designs an integrated radio and antenna systems. The company was founded in 2007 and is headquartered in Sterling, VA. | Consumer Services |
New Venturetec AG /Venture Capital/
New Venturetec AG /Venture Capital/ Investment ManagersFinance New Venturetec AG is a venture capital firm was founded by Peter A. Friedli on August 11, 1997 and is headquartered in Zug, Switzerland. | Finance |
- Stock Market
- Insiders
- Peter A. Friedli